The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The role of MRD in guiding maintenance treatment decisions in multiple myeloma
Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, comments on the role of measurable residual disease (MRD) in guiding maintenance treatment decisions in multiple myeloma. Dr Anderson suggests that patients with MRD-positive status should continue on doublet therapy with daratumumab and lenalidomide, especially those with high-risk features or high-risk chromosomes. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In general, in patients that are still MRD positive, I would tend to favor continuing them on double therapy with daratumumab and lenalidomide rather than lenalidomide alone. Certainly, especially if they have any high-risk features or high-risk chromosomes, but even just having MRD positive after treatment would be in favor, I would favor continuing the Dara. We have a couple of other studies that looked at daratumumab and lenalidomide after stem cell transplant, both the Griffin and the Perseus studies...
In general, in patients that are still MRD positive, I would tend to favor continuing them on double therapy with daratumumab and lenalidomide rather than lenalidomide alone. Certainly, especially if they have any high-risk features or high-risk chromosomes, but even just having MRD positive after treatment would be in favor, I would favor continuing the Dara. We have a couple of other studies that looked at daratumumab and lenalidomide after stem cell transplant, both the Griffin and the Perseus studies. And they did those a little bit differently in the Griffin. The daratumumab was stopped even if they were MRD positive, and we did not see great outcomes in the double-hit chromosome patients, for example. Whereas in the Perseus study, the daratumumab is continued as long as they’re MRD positive. And so we’re hoping that translates into longer-term favorable outcomes for even the high-risk patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Ad board activity for Janssen (Johnson & Johnson), Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Karyopharm, Pfizer, Cellectar, Sanofi, Prothena.
